Get started
DexCom, Inc.DexCom, Inc.DexCom, Inc.

DexCom, Inc.

No trades
See on Supercharts
OverviewFinancialsNewsIdeasMindsTechnicalsForecastsSeasonalsBondsETFs

Chart


Full chart

Key facts today


On December 7, 2025, a class action lawsuit was filed against DexCom, Inc. for allegedly making false statements about its business and unauthorized design changes to its G6 and G7 glucose monitors.
Analyze the impactAnalyze the impact

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪20.53 B‬ CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
32.019
Basic EPS (TTM)
1.467 CHF
Net income (FY)
‪523.30 M‬ CHF
Revenue (FY)
‪3.66 B‬ CHF
Shares float
‪384.35 M‬
Beta (1Y)
1.41

Employees


Employees (FY)
‪10.3 K‬
Change (1Y)
+700 +7.29%
Revenue / Employee (1Y)
‪355.61 K‬ CHF
Net income / Employee (1Y)
‪50.81 K‬ CHF

About DexCom, Inc.


Sector
Health Technology
Industry
Medical Specialties
CEO
Jacob S. Leach
Website
dexcom.com
Headquarters
San Diego
Founded
1999
ISIN
US2521311074
FIGI
BBG00LVD7CL3
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Check out other big names from the same industry as DC4.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds


DXCM5813816
DexCom, Inc. 0.375% 15-MAY-2028
Yield to maturity
—
Maturity date
May 15, 2028

See all DC4 bonds 

ETFs


VTI
Vanguard Total Stock Market ETF
Weight
0.03%
Market value
‪717.04 M‬
USD
VOO
Vanguard S&P 500 ETF
Weight
0.04%
Market value
‪569.53 M‬
USD
QQQ
Invesco QQQ Trust Series I
Weight
0.13%
Market value
‪543.44 M‬
USD
VO
Vanguard Mid-Cap ETF
Weight
0.25%
Market value
‪502.46 M‬
USD
IVV
iShares Core S&P 500 ETF
Weight
0.04%
Market value
‪321.85 M‬
USD
VUG
Vanguard Growth ETF
Weight
0.09%
Market value
‪321.08 M‬
USD
SPY
SPDR S&P 500 ETF
Weight
0.04%
Market value
‪305.40 M‬
USD
SPY
SPDR S&P 500 ETF Trust
Weight
0.04%
Market value
‪305.40 M‬
USD
VOT
Vanguard Mid-Cap Growth ETF
Weight
0.59%
Market value
‪196.30 M‬
USD
XLV
State Street Health Care Select Sector SPDR ETF
Weight
0.46%
Market value
‪184.57 M‬
USD
IWP
iShares Russell Mid-Cap Growth ETF
Weight
0.85%
Market value
‪172.46 M‬
USD

Explore more ETFs 

Frequently Asked Questions


The current price of DC4 is 52.389 CHF — it has increased by 13.28% in the past 24 hours. Watch DexCom, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange DexCom, Inc. stocks are traded under the ticker DC4.
DC4 stock has risen by 13.28% compared to the previous week, the month change is a −1.04% fall, over the last year DexCom, Inc. has showed a −11.99% decrease.
We've gathered analysts' opinions on DexCom, Inc. future price: according to them, DC4 price has a max estimate of 89.95 CHF and a min estimate of 54.61 CHF. Watch DC4 chart and read a more detailed DexCom, Inc. stock forecast: see what analysts think of DexCom, Inc. and suggest that you do with its stocks.
DC4 reached its all-time high on Nov 1, 2021 with the price of 570.749 CHF, and its all-time low was 46.248 CHF and was reached on Nov 18, 2025. View more price dynamics on DC4 chart.
See other stocks reaching their highest and lowest prices.
DC4 stock is 11.72% volatile and has beta coefficient of 1.41. Track DexCom, Inc. stock price on the chart and check out the list of the most volatile stocks — is DexCom, Inc. there?
Today DexCom, Inc. has the market capitalization of ‪20.53 B‬, it has increased by 1.39% over the last week.
Yes, you can track DexCom, Inc. financials in yearly and quarterly reports right on TradingView.
DexCom, Inc. is going to release the next earnings report on Feb 5, 2026. Keep track of upcoming events with our Earnings Calendar.
DC4 earnings for the last quarter are 0.49 CHF per share, whereas the estimation was 0.46 CHF resulting in a 5.85% surprise. The estimated earnings for the next quarter are 0.52 CHF per share. See more details about DexCom, Inc. earnings.
DexCom, Inc. revenue for the last quarter amounts to ‪963.20 M‬ CHF, despite the estimated figure of ‪942.84 M‬ CHF. In the next quarter, revenue is expected to reach ‪998.79 M‬ CHF.
DC4 net income for the last quarter is ‪226.05 M‬ CHF, while the quarter before that showed ‪142.65 M‬ CHF of net income which accounts for 58.46% change. Track more DexCom, Inc. financial stats to get the full picture.
No, DC4 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 8, 2025, the company has ‪10.3 K‬ employees. See our rating of the largest employees — is DexCom, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. DexCom, Inc. EBITDA is ‪814.10 M‬ CHF, and current EBITDA margin is 20.28%. See more stats in DexCom, Inc. financial statements.
Like other stocks, DC4 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DexCom, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So DexCom, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating DexCom, Inc. stock shows the sell signal. See more of DexCom, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.